Stock Markets

Daily coverage of equity markets, sectors, and major indices.

In-depth reporting on U.S. and global stock markets, including index performance, sector rotation, earnings reactions, volatility trends, and notable single-stock moves. Designed to help traders and investors understand what is driving price action across equities.

Articles

9,365 total articles

National Vision’s Strategic Shift Boosts Revenue, Margins, and Product Mix

National Vision’s Strategic Shift Boosts Revenue, Margins, and Product Mix

National Vision has seen a significant stock rally and improved financial performance driven by a deliberate pivot toward managed-care customers, higher-value product assortment including smart eyewear, and a technology-led modernization of its in-store experience. CEO Alex Wilkes says the company is reallocating marketing and reshaping assortment …

Zoox Widens U.S. Robotaxi Reach, Adds San Francisco and Las Vegas; Begins Austin and Miami Road Tests

Zoox Widens U.S. Robotaxi Reach, Adds San Francisco and Las Vegas; Begins Austin and Miami Road Tests

Zoox, the autonomous vehicle unit owned by Amazon, announced an expansion of its robotaxi operations in San Francisco and Las Vegas and will begin public-road testing of its purpose-built vehicles in Austin and Miami. The company will focus its San Francisco growth on high-demand neighborhoods and widen coverage along the Las Vegas Strip, while Aus…

Insider trades on Monday: Large purchases at AdaptHealth and Marketwise; notable sales at GitLab and Powell

Insider trades on Monday: Large purchases at AdaptHealth and Marketwise; notable sales at GitLab and Powell

Insider filings made public on Monday show sizable purchases at AdaptHealth Corp and Marketwise, Inc., plus a very large institutional acquisition in Rare Element Resources Ltd. Several major sales were also reported, including transactions at GitLab Inc., Powell Industries and UWM Holdings Corp. The activity highlights concentrated confidence by s…

Ocugen Shares Slip After Phase 2 12-Month Readout Shows Structural Preservation in Geographic Atrophy

Ocugen Shares Slip After Phase 2 12-Month Readout Shows Structural Preservation in Geographic Atrophy

Ocugen reported 12-month results from its Phase 2 ArMaDa trial of OCU410 for geographic atrophy secondary to dry age-related macular degeneration. The optimal dose produced a statistically significant 31% reduction in lesion growth versus control and a 27% slower ellipsoid zone loss compared with control. The company recorded no serious adverse eve…

TSX Futures Drift Lower as Oil Rebounds amid Renewed Middle East Strikes

TSX Futures Drift Lower as Oil Rebounds amid Renewed Middle East Strikes

Futures tied to Canada’s principal stock index slipped on Tuesday as investors digested renewed missile and drone strikes across the Middle East. Oil pushed back above $100 a barrel, while U.S. futures also moved lower. Market participants are balancing tentative optimism about a de-escalation with persistent geopolitical risks that are keeping ene…

Klarna Boosts US Funding Line to $2 Billion as Shares Tick Higher

Klarna Boosts US Funding Line to $2 Billion as Shares Tick Higher

Klarna said it has increased its financing arrangement with Elliott Investment Management to $2 billion and extended the agreement to a three-year term, enabling the company to support up to $17 billion in U.S. loan originations while keeping underwriting and servicing responsibilities in-house. The announcement followed strong growth in Klarna's U…

Morgan Stanley Keeps 'Overweight' on ASML but Sees Limited Near-Term Upside

Morgan Stanley Keeps 'Overweight' on ASML but Sees Limited Near-Term Upside

Morgan Stanley maintained an "overweight" rating on ASML Holding NV and held its €1,400 price target, while cautioning that near-term upside may be constrained in 2026 as demand for extreme ultraviolet lithography systems is concentrated toward the second half of the year. The brokerage updated shipment and region assumptions, raising its 2027 ship…

Karyopharm Shares Jump After Mixed Phase 3 SENTRY Readout

Karyopharm Shares Jump After Mixed Phase 3 SENTRY Readout

Karyopharm Therapeutics shares climbed 10% after the company reported mixed results from its Phase 3 SENTRY trial testing selinexor plus ruxolitinib in frontline myelofibrosis. The study met a co-primary endpoint for spleen volume reduction but failed to achieve the co-primary endpoint for symptom improvement. The company reported an encouraging ov…

Private-credit strains spread to banks and funds as investors pull back

Private-credit strains spread to banks and funds as investors pull back

Growing anxiety in the private-credit market is prompting major U.S. banks to tighten financing and several large private-credit funds to limit redemptions. Concerns about valuations, transparency and exposures to troubled borrowers - including recent bankruptcies - have weighed on sentiment. Data from Moody's show substantial bank links to private…

Top Shareholder Demands CEO and Senior Team Step Down at Delivery Hero

Top Shareholder Demands CEO and Senior Team Step Down at Delivery Hero

Aspex, a major shareholder in Delivery Hero, has written to the company’s supervisory board calling for the removal of CEO Niklas Oestberg and senior executives. The investor argues that the current strategy is flawed, operational performance is lagging peers and the business is suffering from compliance and control shortcomings. Delivery Hero has …